Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the release date for its third quarter 2024 financial results. The company will disclose these results after the market closes on Wednesday, November 6, 2024.
Following the release, Veracyte's management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will provide a general business update and discuss the financial results. Investors and interested parties can access the live webcast through the company's website or via the provided link: https://edge.media-server.com/mmc/p/kzh3s376.
For those unable to attend the live event, a webcast replay will be made available on Veracyte's investor relations website. Conference call dial-in information can be obtained by registering at the provided link.
Veracyte, Inc. (Nasdaq: VCYT), una delle principali aziende nel campo della diagnostica per il cancro, ha annunciato la data di rilascio dei risultati finanziari del terzo trimestre 2024. L'azienda svelerà questi risultati dopo la chiusura del mercato di mercoledì 6 novembre 2024.
Dopo il rilascio, il team di gestione di Veracyte terrà una conference call e webcast alle 16:30 Eastern Time dello stesso giorno. Questo evento fornirà un aggiornamento generale sull'andamento dell'azienda e discuterà i risultati finanziari. Gli investitori e le parti interessate possono accedere al webcast in diretta tramite il sito web dell'azienda o attraverso il link fornito: https://edge.media-server.com/mmc/p/kzh3s376.
Per chi non può partecipare all'evento in diretta, sarà disponibile una registrazione del webcast sul sito delle relazioni con gli investitori di Veracyte. Le informazioni per partecipare alla conference call possono essere ottenute registrandosi al link fornito.
Veracyte, Inc. (Nasdaq: VCYT), una de las principales empresas de diagnóstico del cáncer, ha anunciado la fecha de publicación de sus resultados financieros del tercer trimestre de 2024. La compañía dará a conocer estos resultados después del cierre del mercado el miércoles 6 de noviembre de 2024.
Después de la publicación, el equipo de gestión de Veracyte llevará a cabo una llamada de conferencia y webcast a las 4:30 p.m. Hora del Este el mismo día. Este evento proporcionará una actualización general del negocio y discutirá los resultados financieros. Los inversores y partes interesadas pueden acceder al webcast en vivo a través del sitio web de la empresa o mediante el enlace proporcionado: https://edge.media-server.com/mmc/p/kzh3s376.
Para aquellos que no pueden asistir al evento en vivo, se hará disponible una repetición del webcast en el sitio web de relaciones con inversionistas de Veracyte. La información para la llamada de conferencia se puede obtener registrándose en el enlace proporcionado.
Veracyte, Inc. (Nasdaq: VCYT)은 주요 암 진단 회사로서 2024년 3분기 재무 결과 발표 일정을 발표했습니다. 회사는 2024년 11월 6일 수요일 시장이 마감된 후 결과를 공개할 예정입니다.
발표 후, Veracyte의 경영진은 같은 날 동부 표준시 오후 4시 30분에 전화 회의 및 웹콘퍼런스를 주최합니다. 이 이벤트에서는 일반적인 사업 업데이트가 제공되고 재무 결과가 논의될 것입니다. 투자자 및 관심 있는 당사자들은 회사 웹사이트 또는 제공된 링크를 통해 라이브 웹캐스트에 접근할 수 있습니다: https://edge.media-server.com/mmc/p/kzh3s376.
라이브 이벤트에 참석할 수 없는 분들을 위해 Veracyte의 투자자 관계 웹사이트에서 웹캐스트 재생을 이용할 수 있습니다. 전화 회의에 관한 정보는 제공된 링크에서 등록하여 확인할 수 있습니다.
Veracyte, Inc. (Nasdaq: VCYT), une entreprise leader dans le domaine des diagnostics du cancer, a annoncé la date de publication de ses résultats financiers du troisième trimestre 2024. L'entreprise dévoilera ces résultats après la clôture du marché le mercredi 6 novembre 2024.
Après la publication, l'équipe de direction de Veracyte animera une conférence téléphonique et un webcast à 16h30, heure de l'Est le même jour. Cet événement fournira une mise à jour générale sur l'entreprise et discutera des résultats financiers. Les investisseurs et les parties intéressées peuvent accéder au webcast en direct via le site web de l'entreprise ou via le lien fourni : https://edge.media-server.com/mmc/p/kzh3s376.
Pour ceux qui ne peuvent pas assister à l'événement en direct, un replay du webcast sera mis à disposition sur le site des relations avec les investisseurs de Veracyte. Les informations pour participer à la conférence téléphonique peuvent être obtenues en s'inscrivant via le lien fourni.
Veracyte, Inc. (Nasdaq: VCYT), ein führendes Unternehmen im Bereich der Krebsdiagnostik, hat das Veröffentlichungsdatum für seine Finanzergebnisse des dritten Quartals 2024 bekannt gegeben. Das Unternehmen wird diese Ergebnisse nach Marktschluss am Mittwoch, den 6. November 2024 offenlegen.
Nach der Veröffentlichung wird das Management-Team von Veracyte eine Konferenzschaltung und Webcast am selben Tag um 16:30 Uhr Eastern Time durchführen. Diese Veranstaltung bietet ein allgemeines Geschäftsupdate und erörtert die finanziellen Ergebnisse. Investoren und interessierte Parteien können über die Unternehmenswebsite oder den bereitgestellten Link auf den Live-Webcast zugreifen: https://edge.media-server.com/mmc/p/kzh3s376.
Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird ein Webcast-Wiedergabe auf der Investor-Relations-Website von Veracyte zur Verfügung gestellt. Informationen zur Teilnahme an der Konferenzschaltung können durch Registrierung unter dem bereitgestellten Link erhalten werden.
- None.
- None.
The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/kzh3s376. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BI945e651d9e5f40acbfaec616e1b85b4e
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016729306/en/
Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545
Media:
Tracy Morris
media@veracyte.com
(650) 380-4413
Source: Veracyte, Inc.
FAQ
When will Veracyte (VCYT) release its Q3 2024 financial results?
What time is Veracyte's (VCYT) Q3 2024 earnings call scheduled for?
How can investors access Veracyte's (VCYT) Q3 2024 earnings webcast?
Where can I find the replay of Veracyte's (VCYT) Q3 2024 earnings call?
